Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Technical advance

Standardisation framework for the Maudsley staging method for treatment resistance in depression

Authors: Abebaw Fekadu, Jacek G. Donocik, Anthony J. Cleare

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Treatment-resistant depression (TRD) is a serious and relatively common clinical condition. Lack of consensus on defining and staging TRD remains one of the main barriers to understanding TRD and approaches to intervention. The Maudsley Staging Method (MSM) is the first multidimensional model developed to define and stage treatment-resistance in “unipolar depression”. The model is being used increasingly in treatment and epidemiological studies of TRD and has the potential to support consensus. Yet, standardised methods for rating the MSM have not been described adequately. The aim of this report is to present standardised approaches for rating or completing the MSM.

Method

Based on the initial development of the MSM and a narrative review of the literature, the developers of the MSM provide explicit guidance on how the three dimensions of the MSM--treatment failure, severity of depressive episode and duration of depressive episode-- may be rated.

Result

The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory (MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension, severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for scoring the third dimension, duration of depressive episode.

Conclusion

The approaches provided should have clinical and research utility in staging TRD. However, in proposing this model, we are fully cognisant that until the pathophysiology of depression is better understood, staging methods can only be tentative approximations. Future developments should attempt to incorporate other biological/ pathophysiological dimensions for staging.
Appendix
Available only for authorised users
Footnotes
1
Italicised words in bracket are added by authors for clarity of reading
 
Literature
1.
2.
Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16–22.PubMed
3.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.CrossRefPubMed
4.
Heslin M, Lappin JM, Donoghue K, Lomas B, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, et al. Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients. Schizophrenia Research. 176(2):417–22.
5.
Tsuang MT, Woolson RF, Fleming JA. Long-term outcome of major psychoses: I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry. 1979;36(12):1295–301.CrossRefPubMed
6.
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179–200.CrossRefPubMed
7.
Berlim MT, Turecki G. Definition, and staging of treatment resistant refractory major depression. Can J Psychiatr. 2007;52:46–54.CrossRef
8.
Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatr. 1958;115:459–64.CrossRefPubMed
9.
Greenblatt M, Grosser GH, Wechsler H. A comparative study of selected antidepressant medications and EST. Am J Psychiatr. 1962;119(2):144–53.CrossRefPubMed
10.
The Medical Research Council. Clinical trial of the treatment of depressive illness: report to the Medical Research Council by its Clinical Psychiatry Committee. British Medical Journal. 1965;1:881–6.CrossRef
11.
Helmchen H. Symptomatology of therapy-resistant depressions. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):145–55.CrossRefPubMed
12.
Helmchen H. Therapy-resistant depression: symptoms and syndromes. Contributions to symptomatology and syndromes. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):139–44.
13.
Lopez-Ibor Alino JJ. Therapeutic resistant depressions: symptoms, resistance and therapy. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):178–87.CrossRefPubMed
14.
Sartorius N. Description and classification of depressive disorders. Contributions for the definition of the therapy-resistance and of therapy resistant depressions. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(2):76–9.CrossRefPubMed
15.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment stepts: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.CrossRefPubMed
16.
Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatr. 2009;166:591–8.CrossRefPubMed
17.
Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, Coupland C. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ. 2001;323(7314):666–9.CrossRefPubMedPubMedCentral
18.
Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91(4):465–71.CrossRefPubMedPubMedCentral
19.
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–59.CrossRefPubMed
20.
Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(Suppl 8):5–12.PubMed
21.
Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18–25.PubMed
22.
Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res. 1995;29(1):43–50.CrossRefPubMed
23.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. The World Journal of Biological Psychiatry. 2013;14(5):334–85.CrossRefPubMed
24.
Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70(2):177–84.CrossRefPubMed
25.
Icick R, Millet É, Curis E, Bellivier F, Lépine J-P. Predictive value of baseline resistance in early response to antidepressants. J Affect Disord. 161:127–35.
26.
Li C-T, Chen M-H, Juan C-H, Huang H-H, Chen L-F, Hsieh J-C, Tu P-C, Bai Y-M, Tsai S-J, Lee Y-C, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014;
27.
Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201(5):369–75.CrossRefPubMed
28.
Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009;70:952–7.CrossRefPubMed
29.
Trevino K. Defining and differentiating treatment-resistant depression: University of Texas Southwestern Medical Center; 2012.
30.
Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012;200(1):52–9.CrossRefPubMed
31.
Martin DM, Alonzo A, Mitchell PB, Sachdev P, Gálvez V, Loo CK. Fronto-extracephalic transcranial direct current stimulation as a treatment for major depression: an open-label pilot study. J Affect Disord. 2011;134(1–3):459–63.CrossRefPubMed
32.
Grant N, Hotopf M, Breen G, Cleare A, Grey N, Hepgul N, King S, Moran P, Pariante C, Wingrove J, et al. Predicting outcome following psychological therapy in IAPT (PROMPT): a naturalistic project protocol. BMC Psychiatry. 2014;14(1):170.CrossRefPubMedPubMedCentral
33.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatr. 2000;157(4 Suppl):1–45.
34.
Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, Dickens C, Ferrier I, Geddes J, Gilbody S, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525.CrossRefPubMed
35.
Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. London: Informa Healthcare; 2015.
36.
Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76–95.CrossRefPubMed
37.
Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707.CrossRefPubMed
38.
39.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Fourth edn. Washington, DC: American Psychiatric Association; 1994.
40.
Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343–96.CrossRefPubMed
41.
National Institute for Health and Clinical Excellence: Clinical guideline 23 (amended) depression: management of depression in primary and secondary care. In.: National Institute for Health and Clinical Excellence; 2007: 34.
42.
The European Agency for the Evaluation of Medicinal Products: Note for guidance on clinical investigation of medicinal products in the treatment of depression In.; 2002.
43.
Charney DS, Miller HL, Licinio J, Salomon R. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. The American textbook of psychopharmacology. Washington, DC: American Psychiatric Press, Inc; 2005. p. 588.
44.
Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23–9.PubMed
45.
Peeters FPML, Ruhe HG, Wichers M, Abidi L, Kaub K, van der Lande HJ, Spijker J, Huibers MJH, Schene AH. The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. J Affect Disord. 2016;205(Supplement C):365–71.CrossRefPubMed
46.
Centers for Medicare and Medicaid Services: Medicare Evidence Development & Coverage Advisory Committee: Panel Proceedings. In: 2016; Baltimore, Maryland: Centers for Medicare and Medicaid Services; 2016.
47.
Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA psychiatry. 2017;74(1):9–10.CrossRefPubMed
48.
Parker GB, Malhi GS, Crawford JG, Thase ME. Identifying “paradigm failures” contributing to treatment-resistant depression. J Affect Disord. 2005;87(2–3):185–91.CrossRefPubMed
49.
Finch J, Sobin P, Carmody T, DeWitt A, Shiwach R. A survey of psychiatrists' attitudes toward electroconvusive therapy. Pscyhiatric Services. 1999;50:264–5.CrossRef
50.
51.
Papakostas GI, Fava M, Thase ME. Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. Biological Psychiatry. 2008;63(7):699–704.
52.
Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol, 2011. 31(4):512-6.
53.
Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336–41.CrossRefPubMed
54.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operatonal criteria. Eur Neuropsychopharmacol. 1999;9:83–91.CrossRefPubMed
55.
56.
Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112(4):302–9.CrossRefPubMed
57.
Andrews G, Jenkins R: Management of Mental Disorders, vol. Vol.1. (UK edition Vol.1). Sydney: WHO Collaborating Centre for Mental Health and Substance Misuse; 1999.
58.
Bech P: Pharmacological treatment of depressive disorders: a review. In: Depressive Disorders. Edited by Maj M, Sartorius N, vol. 1, Secod edn. Chichester: Wiley; 2002: 99.
59.
Debattista C, Schatzberg A: Drug augmentation. In: Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Edited by Sadock B, Sadock V, 8th ed edn. Philadelphia: Lippincott Williams & Wilkins; 2005: 3005.
60.
Johnstone E, Lawler P, Stevens M, Deakin JFW, Frith CD, McPherson K, Crow TJ. the northwick park electroconvulsive therapy trial. Lancet. 1980;316(8208–8209):1317–20.CrossRef
61.
Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–5.CrossRefPubMed
62.
Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. Symptom differences between depressed outpatients who are in remission according to the Hamilton depression rating scale who do and do not consider themselves to be in remission. J Affect Disord. 2012;142(1–3):77–81.CrossRefPubMed
63.
Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. How should residual symptoms be defined in depressed patients who have remitted? Compr Psychiatry. 2013;54(2):91–6.CrossRefPubMed
64.
Zimmerman M, Martinez JA, Attiullah N, Friedman M, Toba C, Boerescu DA, Rahgeb M. Why do some depressed outpatients who are in remission according to the Hamilton depression rating scale not consider themselves to be in remission? J Clin Psychiatry. 2012;73(6):790–5.CrossRefPubMed
65.
Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. 2008;42(10):797–801.CrossRefPubMed
66.
Zimmerman M, Posternak MA, Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Compr Psychiatry. 2007;48(2):113–7.CrossRefPubMed
67.
Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The longitudinal interval follow-up evaluation a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44:540–8.CrossRefPubMed
68.
Schlaepfer TE, Ågren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S. The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol. 2012;26(5):587–602.CrossRefPubMed
69.
Blom MB, Spinhoven P, Hoffman T, Jonker K, Hoencamp E, Haffmans PM, van Dyck R: Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007 2007, 104:119–126.
70.
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–41. quiz 1666CrossRefPubMed
71.
Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20(4):483–7.CrossRefPubMed
72.
Rubenstein LV, Rayburn NR, Keeler EB, Ford DE, Rost KM, Sherbourne CD. Predicting outcomes of primary care patients with major depression: development of a depression prognosis index. Psychiatr Serv. 2007;58:1049–56.CrossRefPubMed
73.
Ezquiaga E, García-López A, de Dios C, Leiva A, Bravo M, Montejo J. Clinical and psychosocial factors associated with the outcome of unipolar major depression: a one year prospective study. J Affect Disord. 2004;79:63–70.CrossRefPubMed
74.
Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA. 1984;252:788–95.CrossRefPubMed
75.
Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry. 1988;153:741–51.CrossRefPubMed
76.
Nasser EH, Overholser JC. Recovery from major depression: the role of support from family, friends, and spiritual beliefs. Acta Psychiatr Scand. 2005;111:125–32.CrossRefPubMed
77.
Parker G, Wilhelm K, Mitchell P, Gladstone G. Predictors of 1-year outcome in depression. Aust N Z J Psychiatry. 2000;34:56–64.CrossRefPubMed
78.
Katon W, Lin E, von Korff M, Bush T, Walker E, Simon G, Robinson P. The predictors of persistence of depression in primary care. J Affect Disord. 1994;31:81–90.CrossRefPubMed
79.
McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542–8.CrossRefPubMed
80.
Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171–80.CrossRefPubMed
81.
Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med. 1997;27:731–6.CrossRefPubMed
82.
Zarate CAJ, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000;61:185–9.CrossRefPubMed
83.
World Health Organisation. The ICD-10 classification of mental and Behavioural disorders clinical descriptions and diagnostic guidelines 10th edn. Geneva: WHO; 1992.
84.
Keller J, Shen L, Gomez RG, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry. 2008;165:872–80.CrossRefPubMedPubMedCentral
85.
Schatzberg AF, Posener JA, De Battista C, Kalehzan M, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry. 2000;157:1095–100.CrossRefPubMed
86.
Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733–45.CrossRefPubMed
87.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders fifth edition, fifth edition edn. Arlington, VA: American Psychiatric Publishing; 2013.
88.
Judd L, Schettler P, Akiskal HS. The prevalence, clinical relevance and public health significance of subthreshold depression. Psychiatr Clin North Am. 2002;25:685–98.CrossRefPubMed
89.
Ruo B, Rumsfeld J, Hlatky M, Liu H, Browner W, Whooley M. Depressive symptoms and health-related quality of life: the heart and soul study. JAMA. 2003;290:215–21.CrossRefPubMedPubMedCentral
90.
Cuijpers P, Smit F, Willemse G. Predicting the onset of major depression in subjects with subthreshold depression in primary care: a prospective study. Acta Psychiatr Scand. 2005;111:133–8.CrossRefPubMed
91.
Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Differences between minimally depressed patients who do and do not consider themselves to be in remission. J Clin Psychiatry. 2005;66(9):1134–8.CrossRefPubMed
92.
Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384–91.CrossRefPubMed
93.
Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry. 1994;55(1):12–9.PubMed
94.
Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord. 2001;64(2–3):261–5.CrossRefPubMed
95.
McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CMJ. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry. 2000;61:518–24.CrossRefPubMed
96.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition text revision. Washington, DC: American Psychiatric Association; 2000.CrossRef
97.
Rane LJ, Fekadu A, Wooderson S, Poon L, Markopoulou K, Cleare AJ. Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome. J Psychiatr Res. 2010;44(15):1082–7.CrossRefPubMed
98.
Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, Johnson CR, Seidman S, Giller C, Haines S, et al. Vagus nerve stimulation (VNS™) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713.CrossRefPubMed
99.
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153(8):985–92.CrossRefPubMed
100.
Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–7.PubMed
101.
Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry 12th edn. London: Wiley-Blackwell; 2015.
102.
Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA, Rahgeb M. Determining remission from depression on two self-report symptom scales: a comparison of the quick inventory of depressive symptomatology and the clinically useful depression outcome scale. Compr Psychiatry. 2012;53(7):1034–8.CrossRefPubMed
103.
Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384–8.CrossRefPubMed
104.
Chapell R, Reston J, Snyder D: Management of Treatment-Resistant Epilepsy. Evidence Report/Technology Assessment No. 77. (Prepared by the ECRI Evidence-based Practice Center under Contract No 290–97-0020.). In.: Healthcare Research and Quality; 2003.
105.
Coryell W, Endicott J, Keller M. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatr. 1990;147:1627–33.CrossRefPubMed
106.
Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. A 25-year longitudinal, comparison study of the outcome of depression. Psychol Med. 2001;31:1347–59.CrossRefPubMed
107.
Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4–11.CrossRefPubMed
108.
Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry. 1986;148:599–601.CrossRefPubMed
Metadata
Title
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Authors
Abebaw Fekadu
Jacek G. Donocik
Anthony J. Cleare
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1679-x

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue

Research article

Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis

Research article

Demographic, psychosocial and clinical factors associated with postpartum depression in Kenyan women

Research article

The “Clinician’s illusion” and the epidemiology, diagnosis and treatment of depressive disorders

Research article

The relationship between college students’ alexithymia and mobile phone addiction: Testing mediation and moderation effects

Research article

Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression

Study protocol

Prospective, randomized, double-blind, placebo-controlled phase IIa clinical trial on the effects of an estrogen-progestin combination as add-on to inpatient psychotherapy in adult female patients suffering from anorexia nervosa